President Trump and other leading conservatives are pushing policies they hope will empower patients to shop more wisely for the health care they need.
Out-of-Pocket Costs
Posted inCost of Care
Should People Who Want GLP-1s Have to Work for Them?
As demand for new weight loss drugs soars, some employers are making workers track their diet and exercise in hopes of limiting use and keeping costs down.
Posted inCost of Care
GLP-1s Are Busting Employer Budgets. Some Are Getting Creative to Lower Costs.
From obesity management programs to rebates and apps, employers are experimenting with new approaches to make GLP-1 costs more sustainable.
Posted inInsurance
The Quiet Cuts Making ACA Enrollment Harder
Higher premiums and penalties have made shopping for Obamacare plans more confusing this year. Navigator programs, a resource for consumers, lost about 90% of federal funding across more than two dozen states earlier this year. How’s open enrollment going so far? “Chaotic,” says one remaining ACA navigator.
Posted inInsurance
What Happens if Obamacare Subsidies Shrink?
Excerpts of a live conversation with two top health economists about how extra federal support has helped millions of Americans access health insurance, and what would happen if that aid went away.
Posted inCost of Care
Can Medicare Afford to Foot the Bill for New Alzheimer’s Drugs?
Recent analyses in JAMA and by the Kaiser Family Foundation raise questions about whether Medicare and its beneficiaries can afford a new wave of Alzheimer’s treatments.
Posted inInsurance
Medicare’s Prescription Drug Plan Makeover
An overhaul of Medicare’s prescription drug benefit will lower costs for seniors while changing incentives for insurers and drugmakers.
Posted inCost of Care
High-Price Drugs Out of Reach for Many on Medicare
Bianca Frogner breaks down new research on the impact subsidies can have for people on Medicare trying to access lifesaving drugs.
Posted inCost of Care
What Happens When Price Transparency Meets Childbirth?
Jamie Daw looks at new research showing the uptake of a hospital price transparency tool for childbirth and its associations with cost of care.
Posted inCost of Care
The Aducanumab Aftermath: The Payer
A costly new Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers.